Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 3/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661859 | 1.00 | MAPK1 (0.55) | MAPK1EGLN1POLBALDH1A1KDM4E | |
| SCHEMBL31661686 | 0.89 | NAAA (0.57) | MAPK1POLBALDH1A1KDM4ENPC1 | |
| SCHEMBL2164508 | 0.89 | NAAA (0.57) | MAPK1POLBALDH1A1KDM4ENPC1 | |
| SCHEMBL5656378 | 0.86 | MAPK1 (0.58) | MAPK1POLBALDH1A1KDM4EALOX5 | |
| SCHEMBL11026787 | 0.86 | MAPK1 (0.58) | MAPK1POLBALDH1A1KDM4EALOX5 | |
| SCHEMBL13577934 | 0.84 | NAAA (0.64) | EGLN1ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12434386 | 0.84 | POLB (0.63) | MAPK1POLBALDH1A1NPC1RAB9A | |
| SCHEMBL5654581 | 0.83 | MAPK1 (0.55) | MAPK1POLBALDH1A1KDM4EALOX5 | |
| SCHEMBL4624092 | 0.83 | MAPK1 (0.55) | MAPK1POLBALDH1A1KDM4EALOX5 | |
| SCHEMBL16545132 | 0.83 | MAPK1 (0.55) | MAPK1POLBALDH1A1KDM4EALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-1100522-B1 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-1100522-B1 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785381-B2 | Oral GLP-1 formulations | EMISPHERE TECHNOLOGIES, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| EP-1696960-B1 | INTRANASAL ADMINISTRATION OF GLUCOSE-REGULATING PEPTIDES | AMYLIN PHARMACEUTICALS INC (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20100160556-A1 | GLP-1 Fusion Peptides Conjugated to Polymer(s), Their Production and Use | BIOCOMPATIBLES UK LTD. (GB) | 2010-06-24 | — | — | US | disclosed |
| US-6693073-B2 | ADMINISTERING VIA THE PULMONARY ROUTE FOMULATION COMPRISING ACTIVE AGENT AND CARRIER COMPRISING AN ACYLATED AMINO ACID, A SULFONATED AMINO ACID, A POLYAMINO ACID OR MIXTURES | EMISPHERE TECHNOLOGIES, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030072740-A1 | Pulmonary delivery of active agents | EMISPHERE TECHNOLOGIES, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1100522-A4 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6440929-B1 | ACYLATED AMINO ACID OR A SULFONATED AMINO ACID | EMISPHERE TECHNOLOGIES, INC. | 2002-08-27 | — | — | US | disclosed |
| EP-1100522-A1 | PULMONARY DELIVERY OF ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006184-A1 | PULMONARY DELIVERY OF ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-02-10 | — | — | WO | disclosed |
| US-5962710-A | Method of preparing salicyloylamino acids | EMISPHERE TECHNOLOGIES, INC. (US) | 1999-10-05 | — | — | US | disclosed |
| WO-1998050341-A1 | METHOD OF PREPARING SALICYLOYLAMINO ACIDS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160556-A1 | GLP-1 Fusion Peptides Conjugated to Polymer(s), Their Production and Use | IAPP, GIPR, GLP1R | MAPK1 2756/4885EGLN1 2657/4885POLB 4791/4885 |
| US-20030072740-A1 | Pulmonary delivery of active agents | ANXA11, ANXA1, PIGS | MAPK1 4731/4885EGLN1 1212/4885POLB 3569/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | MAPK1 3137/4885EGLN1 3371/4885POLB 2682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.